Norovirus: Takeda vaccine candidate in human clinical trials
by Press Release from Outbreak News Today on (#1HTWQ)
Takeda Pharmaceutical Company Limited today announced that it has dosed the first subject in a Phase 2b field efficacy trial of Takeda's norovirus vaccine candidate (TAK-214), the only norovirus vaccine candidate in human clinical trials. The Phase 2b, double-blind, randomized, placebo-controlled trial involves healthy male or female adults aged 18 - 49 years. It will ["]
